Sean M.
- Country
- Ireland
- Department
- Oncology
Research Overview
- Phase 1/2 Evaluation of Synthetic Cannabinoid ART27.13 for Cancer Anorexia and Weight Loss in Oncology Patients
- Evaluation of BT8009 Monotherapy and BT8009 with Pembrolizumab Versus Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
- Phase 3 Open-Label Comparison of Ifinatamab Deruxtecan and Docetaxel in Metastatic Castration-Resistant Prostate Cancer
Data & Insights
Has run more than one trial at 38 of 174 partner sites.
Specializations
Oncological Focus
This investigator specializes in the treatment of urothelial cancer, with particular emphasis on advanced disease states including locally advanced and metastatic conditions.
- Advanced Urological Oncology
- Metastatic Disease Management
The investigator's work encompasses innovative therapeutic approaches in urological cancer treatment.
Therapeutic Expertise
The investigator demonstrates expertise in combination therapy approaches, particularly in the context of immunotherapy integration for urological cancers.
- Novel Treatment Combinations
- Immunotherapy Applications
- Treatment Response Assessment
Their work involves evaluating various therapeutic strategies for optimal patient outcomes.
Clinical Assessment
The investigator utilizes advanced methodologies for evaluating treatment effectiveness, including response evaluation criteria and independent review processes.
- Treatment Response Monitoring
- Disease Progression Assessment
- Clinical Outcome Evaluation
Their expertise includes systematic evaluation of therapeutic interventions in oncology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.